ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[Study of the Protective Effect and Mechanism of Inclisiran on Renal Tissue in a Type 2 Diabetes Mouse Model via the Transforming Growth Factor-β Pathway].
Hongqian Li, Bo Chen, Xin Xiang, Ling Qi, Dongmei Zhang, Yuhan Tang, Liling Zhang, Santao Ou, Ling Xue, Weihua Wu
Abstract readEnglish Abstract
In one paragraphArticle in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Hongqian Li// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.ORCID 0009-0004-9880-4687 Bo Chen// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Xin Xiang// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Ling Qi// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Dongmei Zhang// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Yuhan Tang// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Liling Zhang// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Santao Ou// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Ling Xue// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.
Weihua Wu// （ 646000）Department of Nephrology, The Affiliated Hospital of Southwest Medical University/Sichuan Provincial Clinical Research Center for Nephrology/Sichuan Provincial Key Laboratory of Metabolic Diseases, Luzhou 646000, China.ORCID 0000-0002-9717-8010 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Objective: To investigate whether the novel proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor Inclisiran exerts protective effects on the kidneys under high-glucose conditions, and to predict whether its mechanism involves the transforming growth factor-β (TGF-β) pathway using proteomic techniques, while constructing its regulatory network. Methods: Healthy male C57BL/6J mice were randomly assigned to four groups: Group A (control, Results: After modeling, blood glucose, urine protein/creatinine ratio, blood creatinine, cholesterol, and other indicators in groups B, C, and D were significantly higher than those in group A, with group B showing the highest values ( Conclusion: Inclisiran may improve the lipid profile of type 2 diabetic mice and reduce the activity of the TGF-β pathway. Its mechanism of action may be related to effects such as extracellular matrix proliferation.
Indexed as
Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Diabetic NephropathiesKidneyTransforming Growth Factor betaAnimalsMaleMiceMice, Inbred C57BLProprotein Convertase 9ProteomicsSignal TransductionProprotein Convertase 9Transforming Growth Factor betaDiabetic kidney diseaseInclisiranProprotein convertase subtilisin/kexin type 9ProteomicsTransforming growth factor-β
Identifiers
PMID41834977
PMCPMC12979993
What Socratic holds
Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390